Fulgent Genetics Stock Beneish M Score

FLGT Stock  USD 18.33  0.46  2.57%   
This module uses fundamental data of Fulgent Genetics to approximate the value of its Beneish M Score. Fulgent Genetics M Score tells investors if the company management is likely to be manipulating earnings. The score is calculated using eight financial indicators that are adjusted by a specific multiplier. Please note, the M Score is a probabilistic model and cannot detect companies that manipulate their earnings with 100% accuracy. Check out Fulgent Genetics Piotroski F Score and Fulgent Genetics Altman Z Score analysis.
For more information on how to buy Fulgent Stock please use our How to Invest in Fulgent Genetics guide.
  
At this time, Fulgent Genetics' Short and Long Term Debt Total is comparatively stable compared to the past year. Net Debt To EBITDA is likely to gain to 1.85 in 2024, whereas Short Term Debt is likely to drop slightly above 4.9 M in 2024. At this time, Fulgent Genetics' EV To Operating Cash Flow is comparatively stable compared to the past year. EV To Free Cash Flow is likely to gain to 170.51 in 2024, whereas Free Cash Flow Yield is likely to drop 0.01 in 2024.
At this time, it appears that Fulgent Genetics is an unlikely manipulator. The earnings manipulation may begin if Fulgent Genetics' top management creates an artificial sense of financial success, forcing the stock price to be traded at a high price-earnings multiple than it should be. In general, excessive earnings management by Fulgent Genetics executives may lead to removing some of the operating profits from subsequent periods to inflate earnings in the following periods. This way, the manipulation of Fulgent Genetics' earnings can lead to misrepresentations of actual financial condition, taking the otherwise loyal stakeholders on to the path of questionable ethical practices and plain fraud.
-3.33
Beneish M Score - Unlikely Manipulator
Elasticity of Receivables

1.0

Focus
Asset Quality

1.28

Focus
Expense Coverage

1.14

Focus
Gross Margin Strengs

1.22

Focus
Accruals Factor

1.14

Focus
Depreciation Resistance

1.0

Focus
Net Sales Growth

0.92

Focus
Financial Leverage Condition

2.97

Focus

Fulgent Genetics Beneish M-Score Indicator Trends

The cure to earnings manipulation is the transparency of financial reporting. It will typically remove the temptation of the top executives to inflate earnings (i.e., to promote the idea of 'winning at any cost'). Because a healthy internal audit department can enhance transparency, the board should promote the auditors' access to all the record-keeping systems across the enterprise. For example, if Fulgent Genetics' auditors report directly to the board (not management), the managers will be reluctant to manipulate simply due to the fear of punishment. On the other hand, the auditors will be free to investigate the ledgers properly because they know that the board has their back.
Current ValueLast YearChange From Last Year 10 Year Trend
Net Receivables52.9 M57.4 M
Significantly Down
Slightly volatile
Total Revenue266.7 M289.2 M
Significantly Down
Slightly volatile
Total Assets1.3 B1.2 B
Sufficiently Up
Slightly volatile
Total Current Assets365.6 M507.8 M
Way Down
Slightly volatile
Non Current Assets Total763.9 M727.5 M
Sufficiently Up
Slightly volatile
Property Plant Equipment119.4 M113.8 M
Sufficiently Up
Slightly volatile
Depreciation And Amortization27.5 M26.1 M
Sufficiently Up
Slightly volatile
Selling General Administrative93.4 M89 M
Sufficiently Up
Slightly volatile
Total Current Liabilities49.4 M73 M
Way Down
Slightly volatile
Non Current Liabilities Total30.5 M29 M
Sufficiently Up
Slightly volatile
Short Term Debt4.9 M5.1 M
Notably Down
Slightly volatile
Short Term Investments326.9 M326.7 M
Slightly Up
Slightly volatile
Long Term Investments466.2 M444 M
Sufficiently Up
Slightly volatile
Gross Profit Margin0.440.3612
Fairly Up
Slightly volatile

Fulgent Genetics Beneish M-Score Driver Matrix

One of the toughest challenges investors face today is learning how to quickly synthesize historical financial statements and information provided by the company, SEC reporting, and various external parties in order to detect the potential manipulation of earnings. Understanding the correlation between Fulgent Genetics' different financial indicators related to revenue, expenses, operating profit, and net earnings helps investors identify and prioritize their investing strategies towards Fulgent Genetics in a much-optimized way. Analyzing correlations between earnings drivers directly associated with dollar figures is the most effective way to find Fulgent Genetics' degree of accounting gimmicks and manipulations.

About Fulgent Genetics Beneish M Score

M-Score is one of many grading techniques for value stocks. It was developed by Professor M. Daniel Beneish of the Kelley School of Business at Indiana University and published in 1999 under the paper titled The Detection of Earnings Manipulation. The Beneish score is a multi-factor model that utilizes financial identifiers to compile eight variables used to classify whether a company has manipulated its reported earnings. The variables are built from the officially filed financial statements to create a final score call 'M Score.' The score helps to identify companies that are likely to manipulate their profits if they show deteriorating gross margins, operating expenses, and leverage against growing revenue.

Depreciation And Amortization

27.45 Million

At this time, Fulgent Genetics' Depreciation And Amortization is comparatively stable compared to the past year.

Fulgent Genetics Earnings Manipulation Drivers

Although earnings manipulation is typically not the result of intentional misconduct by the c-level executives, it is still a widespread practice by the senior management of public companies such as Fulgent Genetics. It is usually done by a series of misrepresentations of various accounting rules and operating activities across multiple financial cycles. The best way to spot the manipulation is to examine the historical financial statement to find inconsistencies in earning reports to find trends in assets or liabilities that are not sustainable in the future.
201920202021202220232024 (projected)
Net Receivables6.6M204.1M143.3M52.7M57.4M52.9M
Total Revenue32.5M421.7M992.6M619.0M289.2M266.7M
Total Assets88.8M700.5M1.3B1.4B1.2B1.3B
Total Current Assets76.8M615.7M1.1B905.6M507.8M365.6M
Net Debt(9.3M)(71.6M)(143.6M)(58.9M)(82.2M)(78.1M)
Operating Income(428K)290.2M104.3M178.5M(72.7M)(69.1M)
Investments(27.9M)(289.9M)(460.9M)(261.3M)38.9M40.8M
Gross Profit Margin0.570.790.780.590.360.44

Fulgent Genetics ESG Sustainability

Some studies have found that companies with high sustainability scores are getting higher valuations than competitors with lower social-engagement activities. While most ESG disclosures are voluntary and do not directly affect the long term financial condition, Fulgent Genetics' sustainability indicators can be used to identify proper investment strategies using environmental, social, and governance scores that are crucial to Fulgent Genetics' managers, analysts, and investors.
Environmental
Governance
Social

About Fulgent Genetics Fundamental Analysis

The Macroaxis Fundamental Analysis modules help investors analyze Fulgent Genetics's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Fulgent Genetics using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Fulgent Genetics based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.

Thematic Opportunities

Explore Investment Opportunities

Build portfolios using Macroaxis predefined set of investing ideas. Many of Macroaxis investing ideas can easily outperform a given market. Ideas can also be optimized per your risk profile before portfolio origination is invoked. Macroaxis thematic optimization helps investors identify companies most likely to benefit from changes or shifts in various micro-economic or local macro-level trends. Originating optimal thematic portfolios involves aligning investors' personal views, ideas, and beliefs with their actual investments.
Explore Investing Ideas  

Additional Tools for Fulgent Stock Analysis

When running Fulgent Genetics' price analysis, check to measure Fulgent Genetics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Fulgent Genetics is operating at the current time. Most of Fulgent Genetics' value examination focuses on studying past and present price action to predict the probability of Fulgent Genetics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Fulgent Genetics' price. Additionally, you may evaluate how the addition of Fulgent Genetics to your portfolios can decrease your overall portfolio volatility.